EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TWF2 Drives Tumor Progression and Sunitinib Resistance in Renal Cell Carcinoma through Hippo Signaling Suppression

Liangmin Fu iD, Wuyuan Liao, Youyan Tan, Hansen Lin, Kun Ye, Xinwei Zhou, Mingjie Lin, Kangbo Huang, Minyu Chen, Jietao Wei, Haoqian Feng, Yuhang Chen und 14 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202506367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Liangmin Fu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 518880, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Kidney Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Science Fund for Distinguished Young Scholars, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) remains a formidable clinical challenge, characterized by a high propensity for metastasis and the frequent emergence of intrinsic or acquired resistance to targeted therapies. However, the molecular mechanisms underlying sunitinib resistance and tumor progression in RCC are not fully understood. This study aims to identify Twinfilin actin‐binding protein ( TWF2 ) as a key mediator of tumor aggressiveness and therapeutic resistance. TWF2 expression is markedly upregulated in RCC cells, particularly in sunitinib‐resistant subtypes, and significantly associated with poor prognosis and therapeutic nonresponsiveness. Functional analyses demonstrate that TWF2 promotes RCC cell invasion, migration, metastasis, and sunitinib resistance by inhibiting the Hippo signaling. Mechanistically, TWF2 interacts with Yes‐associated protein (YAP) via the binding residues: TWF2 M99 and YAP M225. By competitively displacing large tumor suppressor kinase 1, TWF2 prevents YAP ubiquitination and degradation, leading to its stabilization and subsequent nuclear translocation. Mutation of the M99 residue abolishes the tumor‐promoting activity of TWF2 . Furthermore, salvianolic acid E is identified as a small‐molecule inhibitor of the TWF2 –YAP interaction, and synergistically enhances sunitinib efficacy in RCC cell lines and patient‐derived xenograft models. These findings highlight TWF2 as a promising therapeutic target for overcoming drug resistance in RCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellSunitinibKidney NeoplasmsDrug Resistance, NeoplasmProtein Serine-Threonine KinasesMicrofilament ProteinsHumansHippo Signaling PathwayCell Line, TumorSignal TransductionAnimalsMiceDisease ProgressionAntineoplastic AgentsFemaleYAP-Signaling ProteinsMaleMice, Nude

Stichwörter der Autor:innen

Hippo signalingTWF2renal cell carcinomasunitinib resistancetumor progression

Substanzen

SunitinibProtein Serine-Threonine KinasesMicrofilament ProteinsAntineoplastic AgentsYAP-Signaling Proteins

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 518880, China.
  • Digestive Diseases Center, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 528406, China.
  • Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
  • Department of Urology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, 518116, China.
  • Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

ORCID-Profile: Liangmin Fu, Li Luo

Förderung

  • National Natural Science Foundation of China
  • National Science Fund for Distinguished Young Scholars
  • China Postdoctoral Science Foundation
  • Guangdong Basic and Applied Basic Research Foundation
  • Medical Scientific Research Foundation of Guangdong Province of China
  • Guangzhou Youth Medical Innovation Practice Research Program
  • Shenzhen Medical Research Fund
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Fu, L., Liao, W., Tan, Y., Lin, H., Ye, K., Zhou, X., Lin, M., Huang, K., Chen, M., Wei, J., Feng, H., Chen, Y., Chen, J., Guan, B., Li, S., Zhang, Z., Yu, A., Feng, Z., Zhang, L., …, & Luo, L. (2025). TWF2 Drives Tumor Progression and Sunitinib Resistance in Renal Cell Carcinoma through Hippo Signaling Suppression. Advanced Science. https://doi.org/10.1002/advs.202506367

Vancouver

Fu L, Liao W, Tan Y, Lin H, Ye K, Zhou X, et al. TWF2 Drives Tumor Progression and Sunitinib Resistance in Renal Cell Carcinoma through Hippo Signaling Suppression. Advanced Science. 2025. doi:10.1002/advs.202506367

BibTeX
@article{Fu2025,
  author = {Fu, Liangmin and Liao, Wuyuan and Tan, Youyan and Lin, Hansen and Ye, Kun and Zhou, Xinwei and Lin, Mingjie and Huang, Kangbo and Chen, Minyu and Wei, Jietao and Feng, Haoqian and Chen, Yuhang and Chen, Jinwei and Guan, Bohong and Li, Shan and Zhang, Zhengkun and Yu, Anze and Feng, Zihao and Zhang, Lizhen and Shu, Guannan and Lu, Jun and Chen, Wei and Pan, Yihui and Yang, Jiefeng and Luo, Junhang and Luo, Li},
  title = {TWF2 Drives Tumor Progression and Sunitinib Resistance in Renal Cell Carcinoma through Hippo Signaling Suppression},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202506367}
}
Kostenlos starten →